Health Care • Biotechnology: Pharmaceutical Preparations
$3.61 ▼ -0.37
(-9.30%)
MKT CAP: $93.4M • VOL: 214.7K
52W L $4 52W H $7
COYA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $7.9M | $3.6M | $6.0M |
| YoY Revenue Growth % | +123.6% | -40.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$22.6M | -$17.2M | -$7.9M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$21.2M | -$14.9M | -$8.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$10.7M | -$10.3M | -$11.2M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$10.7M | -$10.3M | -$11.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $46.8M | $38.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $43.0M | $39.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR COYA.